http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-PI0615615-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d6fee72c6528e7b5733566a1c032ada6 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D265-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D237-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-535 |
| filingDate | 2006-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4354bea6fb81152b4639c3b50a951b3d |
| publicationDate | 2012-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-PI0615615-A2 |
| titleOfInvention | pharmaceutical compositions and treatment of a neoplastic disease or proliferative disorder in humans based on theramutein modulators |
| abstract | PHARMACEUTICAL COMPOSITIONS AND TREATMENT OF A NEOPLASTIC DISEASE OR A RPOLIFERATIVE DISORDER IN HUMANS BASED ON THERAMUTEIN MODULATORS. This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and new methods of identifying those variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by mutated genes, whose variants always appear or are at least identified as arising after exposure to a chemical agent that is known as an inhibitor or activator of the protein endogenous without corresponding mutation. |
| priorityDate | 2005-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 413.